Table 1 Demographics, clinical characteristics and treatment of patients with COVID-19
From: Abnormal immunity of non-survivors with COVID-19: predictors for mortality
| Â | Total (539) | Non-survivor (125) | Survivor (414) | P value |
|---|---|---|---|---|
Age (years) | 58 (43–69) | 70 (61.5–80) | 54 (37–65) | < 0.0001 |
Gender | Â | Â | Â | 0.015 |
 Male | 255 (47.3%) | 71 (56.8%) | 184 (44.4%) |  |
 Female | 284 (52.7%) | 54 (43.2%) | 230 (55.6%) |  |
Chronic medical illness | 242 (44.9%) | 88 (70.4%) | 154 (37.2%) | < 0.0001 |
Chronic obstructive lung disease | 22 (4.1%) | 12 (9.6%) | 10 (2.4%) | < 0.0001 |
Diabetes | 58 (10.9%) | 25 (20.0%) | 34 (8.2%) | < 0.0001 |
Hypertention | 140 (26.0%) | 62 (49.6%) | 78 (18.8%) | < 0.0001 |
Coronary heart disease | 37 (6.9%) | 20 (16.0%) | 17 (4.1%) | < 0.0001 |
Cerebrovascular diseases | 19 (3.5%) | 15 (12.0%) | 4 (1.0%) | < 0.0001 |
Hepatitis | 11 (2.0%) | 3 (2.4%) | 8 (1.9%) | 0.746 |
Malignant tumour | 23 (4.3%) | 11 (8.8%) | 12 (2.9%) | 0.0042 |
Chronic kidney disease | 8 (1.5%) | 6 (4.8%) | 2 (0.5%) | 0.0005 |
Immunodeficiency disease | 2 (0.4%) | 0 (0.0%) | 2 (0.5%) | 0.436 |
Time from illness onset to death or discharge, days | 13 (7–20) | 7 (4–11) | 15 (9–21) | < 0.0001 |
Signs and symptoms at admission | ||||
 Fever | 420 (77.9%) | 110 (88%) | 310 (74.9) | 0.001 |
 Rhinorrhoea | 6 (1.1%) | 2 (1.6%) | 4 (1.0%) | 0.945 |
 Cough | 332 (61.6%) | 81 (64.8%) | 251 (60.6%) | 0.402 |
 Expectoration | 161 (29.9%) | 48 (38.4%) | 113 (27.3%) | 0.017 |
 Chest tightness | 187 (34.7%) | 73 (58.4%) | 114 (27.5%) | < 0.0001 |
 Dyspnea | 187 (34.7%) | 78 (62.4%) | 98 (23.7%) | < 0.0001 |
 Fatigue | 261 (48.4%) | 78 (62.4%) | 183 (44.2%) | < 0.0001 |
 Nausea | 9 (1.7%) | 5 (4.0%) | 4 (1.0%) | 0.02 |
 Diarrhea | 58 (10.8%) | 8 (6.4%) | 50 (12.1%) | 0.073 |
Clinical Classification | Â | Â | Â | < 0.0001 |
 Non-severe | 133 (24.7%) | 2 (1.6%) | 131 (31.6%) |  |
 Severe | 406 (75.3%) | 123 (98.4%) | 283 (68.4%) |  |
Treatment | ||||
 Antibiotic drug | 374 (69.4%) | 118 (94.4%) | 256 (61.8%) | < 0.0001 |
 Antiviral therapy or Chinese Medicine | 225 (41.7%) | 58 (46.4%) | 167 (40.3%) | 0.228 |
 Lianhua Qingwen | 301 (55.8%) | 40 (32.0%) | 261 (63.0%) | <  0.0001 |
 Oseltamivir | 157 (29.1%) | 48 (38.4%) | 109 (26.3%) | 0.0092 |
 Arbidol | 370 (68.6%) | 65 (52.0%) | 305 (73.7%) | < 0.0001 |
 Lopinavir/ritonavir | 32 (5.9%) | 18 (14.4%) | 14 (3.4%) | < 0.0001 |
 Human immunoglobulin | 250 (38.4%) | 91 (72.8%) | 159 (38.4%) | < 0.0001 |
 Alpha-interferon | 170 (31.5%) | 34 (27.2%) | 136 (32.9%) | 0.233 |
 Thymosin | 59 (10.9%) | 20 (16.0%) | 39 (9.4%) | 0.039 |
 Glucocorticoids | 249 (46.2%) | 89 (71.2%) | 160 (38.6%) | < 0.0001 |